

Printed as of 7/1/2025

Disclosures

Personal Commercial (3)					
Relationship Category	Compensation Level	Topic Area(s)			
Consultant Fees/Honoraria	Modest (< \$5,000)	General Cardiology			
Research/Research Grants	Modest (< \$5,000)	Arrhythmias and Clinical EP			
Consultant Fees/Honoraria	Significant (>= \$5,000)	Arrhythmias and Clinical EP			
	Consultant Fees/Honoraria Research/Research Grants	Consultant Fees/Honoraria Modest (< \$5,000) Research/Research Grants Modest (< \$5,000)			

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (1)

Non-Commercial Enity Name	Relationship Category	Compensation Level	Topic Area(s)
Self			
TRINDS (Neuromuscular Disease) † TRINDS	Data Safety Monitoring Board	Modest (< \$5,000)	Heart Failure and Cardiomyopathies

Clinical Trial Enroller (2)

Trial Name	Trial Sponsor Trial Funding Source
Gene Therapy for ACM Due to a PKP2 Pathogenic Variant (ClinicalTrials.gov ID NCT06109181)	Lexeo
Open-label, Dose Escalation Study of Safety and Preliminary Efficacy of TN-401 in Adults With PKP2 Mutation-associated ARVC (RIDGE-1) (ClinicalTrials.gov ID NCT06228924)	Tenaya

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (2)

Year	Case Title	Represented	Description	Compensation
Self				
2023	Renal failure, sudden cardiac death	Defendant	as above.	Significant (>= \$5,000)
2022	Inherited Cardiomyopathy	Defendant <i>† none</i>	Inherited Cardiomyopathy	Modest (< \$5,000)

† Commercial Funding Source | *‡* Trial Name

Agreement

Certified Education Attestation | Signed on 9/15/2024

URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement

Confidentiality, Disclosure and Assignment Agreement | Signed on 9/15/2024

URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement

Embargo | Signed on 9/15/2024

URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement

On-Going Obligation Agreement | Signed on 9/15/2024

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private

endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.